These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358 [TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer. Fu XL; Fang Z; Shu LH; Tao GQ; Wang JQ; Rui ZL; Zhang YJ; Tian ZQ Oncotarget; 2017 May; 8(21):34340-34351. PubMed ID: 28423720 [TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials. Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752 [TBL] [Abstract][Full Text] [Related]
5. Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin. Martin LK; Bekaii-Saab T J Natl Compr Canc Netw; 2013 Mar; 11(3):298-307; quiz 307. PubMed ID: 23486456 [TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T; Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C; Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000 [TBL] [Abstract][Full Text] [Related]
8. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919 [TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin-based adjuvant chemotherapy rather than fluorouracil-based chemotherapy in rectal cancer is more efficient to decrease distant metastasis and increase survival after preoperative chemoradiotherapy and surgery: a meta-analysis. Song JH; Lee JH; Kim SH; Um JW; Int J Colorectal Dis; 2022 Mar; 37(3):649-656. PubMed ID: 35050402 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant-intensified treatment for rectal cancer: time to change? Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984 [TBL] [Abstract][Full Text] [Related]
11. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer. Sastre J; Custodio A; Sanchez JC; Ortega L; Rodriguez L; Puente J; Corona J; Alfonso R; de las Heras M; Dıaz-Rubio E Anticancer Drugs; 2011 Feb; 22(2):185-90. PubMed ID: 21218606 [TBL] [Abstract][Full Text] [Related]
12. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U; Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684 [TBL] [Abstract][Full Text] [Related]
13. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). Chakravarthy AB; Zhao F; Meropol NJ; Flynn PJ; Wagner LI; Sloan J; Diasio RB; Mitchell EP; Catalano P; Giantonio BJ; Catalano RB; Haller DG; Awan RA; Mulcahy MF; O'Brien TE; Santala R; Cripps C; Weis JR; Atkins JN; Leichman CG; Petrelli NJ; Sinicrope FA; Brierley JD; Tepper JE; O'Dwyer PJ; Sigurdson ER; Hamilton SR; Cella D; Benson AB Oncologist; 2020 May; 25(5):e798-e807. PubMed ID: 31852811 [TBL] [Abstract][Full Text] [Related]
14. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study. Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662 [TBL] [Abstract][Full Text] [Related]
15. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Marco MR; Zhou L; Patil S; Marcet JE; Varma MG; Oommen S; Cataldo PA; Hunt SR; Kumar A; Herzig DO; Fichera A; Polite BN; Hyman NH; Ternent CA; Stamos MJ; Pigazzi A; Dietz D; Yakunina Y; Pelossof R; Garcia-Aguilar J; Dis Colon Rectum; 2018 Oct; 61(10):1146-1155. PubMed ID: 30192323 [TBL] [Abstract][Full Text] [Related]
16. Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064). Hüttner FJ; Probst P; Kalkum E; Hackbusch M; Jensen K; Ulrich A; Büchler MW; Diener MK Syst Rev; 2018 Jan; 7(1):11. PubMed ID: 29357929 [TBL] [Abstract][Full Text] [Related]
17. Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. Margalit O; Mamtani R; Kopetz S; Yang YX; Lawrence YR; Abu-Gazala S; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B Oncologist; 2019 Aug; 24(8):e671-e676. PubMed ID: 30696723 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials. Tamburini E; Tassinari D; Ramundo M; De Stefano A; Viola MG; Romano C; Elia MT; Zanaletti N; Rudnas B; Casadei-Gardini A; Delrio P; Toma I; Granata V; Petrucelli L; Avallone A Crit Rev Oncol Hematol; 2022 Apr; 172():103627. PubMed ID: 35202817 [TBL] [Abstract][Full Text] [Related]
19. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104 [TBL] [Abstract][Full Text] [Related]
20. Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer. Loree JM; Kennecke HF; Lee-Ying RM; Goodwin RA; Powell ED; Tang PA; Price Hiller JA; Vickers MM; Cheung WY Am J Clin Oncol; 2018 Jul; 41(7):643-648. PubMed ID: 27819876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]